Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Kroupova J et al. | 2007 | intact cell/cell culture, A549 (human adenocarcinoma cell line) | magnetic field, 50/60 Hz | 2 mT |
An GZ et al. | 2015 | intact cell/cell culture, BALB/3T3 cells (embryonal mouse fibroblasts) | magnetic field, 50/60 Hz | 2.3 mT |
Marcantonio P et al. | 2010 | intact cell/cell culture, BE(2)C cells (human neuroblastoma cells) | magnetic field, low frequency, 50/60 Hz, co-exposure | 1 mT |
Tekam CKS et al. | 2023 | intact cell/cell culture, C6 glial cells, animal, rat/Wistar | 50/60 Hz, magnetic field, signals/pulses | - |
Wu X et al. | 2014 | intact cell/cell culture, FL cells (human amniotic cells) | magnetic field, 50/60 Hz | 0.4 mT |
Eremenko T et al. | 1997 | intact cell/cell culture, Friend erythroleukemia cell line (clone 745 A) | magnetic field, geomagnetic field, 50/60 Hz, shielding/field deprivation | 0.0025 nT–70 µT |
Cios A et al. | 2021 | intact cell/cell culture, HEK293 (kidney cells), 786-O, 769-P, and Caki1 (clear cell renal carcinoma cell lines) | magnetic field, 50/60 Hz | 4.5 mT |
Manni V et al. | 2002 | intact cell/cell culture, HaCaT cells (human keratinocytes cell line) | magnetic field, 50/60 Hz | 2 mT |
Rieti S et al. | 2004 | intact cell/cell culture, HaCaT cells (human keratinocytes cell line) | magnetic field, 50/60 Hz | 1 mT |
Lisi A et al. | 2006 | intact cell/cell culture, HaCaT cells (human keratinocytes cell line) | magnetic field, 50/60 Hz | 1 mT |
Cricenti A et al. | 2007 | intact cell/cell culture, HaCaT cells (human keratinocytes cell line) | magnetic field, 50/60 Hz | 1 mT |
Cricenti A et al. | 2008 | intact cell/cell culture, HaCaT cells (human keratinocytes) | magnetic field, 50/60 Hz | 1 mT |
Mattsson MO et al. | 2001 | intact cell/cell culture, Jurkat cells (clone E6-1; T-lymphocyte hybridoma cell line) from three different sources | magnetic field, 50/60 Hz, static magnetic field, shielding/field deprivation | 150 µT |
Paradisi S et al. | 1993 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz | 2.5 mT |
Ayse IG et al. | 2010 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, low frequency, 50/60 Hz, co-exposure | 5 mT |
Pozzi D et al. | 2007 | intact cell/cell culture, LAN-5 cells (human neuroblastoma cell line) | magnetic field, 50/60 Hz | 2 mT |
Lee JH et al. | 2000 | intact cell/cell culture, MC3T3-E1 cells (mouse osteoblast-like cell line) | magnetic field, 50/60 Hz | 700 µT |
Supino R et al. | 2001 | intact cell/cell culture, MCF-7 (breast cancer cell line) and normal fibroblasts | magnetic field, 50/60 Hz | 20–500 µT |
Lazzarini R et al. | 2023 | intact cell/cell culture, MDA-MB-231 cells (breast cancer cell line) and MDA-MB-231 (human breast cell line) | magnetic field, 50/60 Hz | - |
Somosy Z et al. | 2002 | intact cell/cell culture, MDCK cells (Madin-Darby canine kidney cell line) | magnetic field, 50/60 Hz, also other exposures without EMF | 100 µT |
Domínguez G et al. | 2021 | intact cell/cell culture, MDCK cells (Madin-Darby canine kidney cell line) | magnetic field, 50/60 Hz | 1–5 mT |
Shoorche AB et al. | 2023 | intact cell/cell culture, MG-63 cells (human osteosarcoma cell line) | magnetic field, low frequency, 50/60 Hz, signals/pulses | - |
Bersani F et al. | 1997 | intact cell/cell culture, NIH3T3 cells (embryonic Swiss albino mouse fibroblast cell line) | magnetic field, signals/pulses, 50/60 Hz | 0.196–1.88 mT |
Saito A et al. | 2009 | intact cell/cell culture, P19 cells (mouse embryonal carcinoma cells) | magnetic field, low frequency, 50/60 Hz | 1–10 mT |
Morabito C et al. | 2010 | intact cell/cell culture, PC-12 cells | magnetic field, low frequency, 50/60 Hz | 0.1–1 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.